{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T11:15:13Z","timestamp":1723288513040},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,4]]},"DOI":"10.7759\/cureus.19257","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T17:33:21Z","timestamp":1636047201000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of Clozapine Titration in the Setting of Cardiac Comorbidities"],"prefix":"10.7759","author":[{"given":"Theja","family":"Bhamidipati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Divadeenam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes OD","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, et al.. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017, 174:216-29. 10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45:789-96.","journal-title":"Arch Gen Psychiatry"},{"key":"ref3","unstructured":"Clozapine REMS Program. (2015). Accessed. July 30, 2021: https:\/\/www.clozapinerems.com."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine","volume":"24","author":"Young CR","year":"1998","unstructured":"Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998, 24:381-90. 10.1093\/oxfordjournals.schbul.a033333","journal-title":"Schizophr Bull"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003","volume":"30","author":"Haas SJ","year":"2007","unstructured":"Haas SJ, Hill R, Krum H, et al.. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007, 30:47-57. 10.2165\/00002018-200730010-00005","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","article-title":"Clozapine\u2010induced cardiotoxicity: a clinical update","volume":"190","author":"Layland J","year":"2009","unstructured":"Layland J, Liew D. Clozapine\u2010induced cardiotoxicity: a clinical update. Med J Aust. 2009, 190:190-2.","journal-title":"Med J Aust"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.06.057","article-title":"What does minor elevation of C-reactive protein signify?","volume":"119","author":"Kushner I","year":"2006","unstructured":"Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify?. Am J Med. 2006, 119:166.e17-28. 10.1016\/j.amjmed.2005.06.057","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omx080","article-title":"Clozapine-induced myocarditis","volume":"2018","author":"Datta T","year":"2018","unstructured":"Datta T, Solomon AJ. Clozapine-induced myocarditis. Oxf Med Case Reports. 2018, 2018:omx080. 10.1093\/omcr\/omx080","journal-title":"Oxf Med Case Reports"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand IS","year":"2005","unstructured":"Anand IS, Latini R, Florea VG, et al.. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005, 112:1428-34. 10.1161\/CIRCULATIONAHA.104.508465","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/75972-management-of-clozapine-titration-in-the-setting-of-cardiac-comorbidities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:03Z","timestamp":1707507363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/75972-management-of-clozapine-titration-in-the-setting-of-cardiac-comorbidities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.19257","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}